← Eichor
Study identifier: NCT06926608 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Actívatexto: Advancing Smoking Cessation and Physical Activity Among Latinos

Condition: Smoking · Smoking Cessation · Physical Inactivity  ·  Sponsor: University of Rochester

PhaseNA
Planned participants408
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this randomized controlled trial is to assess the efficacy of Actívatexto (Aim 1) and the mediators of the presumed treatment effect (Aim 2) among Latino adults who smoke. Actívatexto is a mobile intervention that integrates four components: 1) a text messaging program that promotes both smoking cessation and physical activity, 2) wearable devices to monitor physical activity, 3) smoking cessation pharmacotherapy \[i.e., nicotine replacement therapies (NRT)\], and 4) an online dashboard where the research team manages participants' incoming and outgoing data from both the text messaging program and wearable devices.

This description comes directly from the study's public registry record.

Talk to the study team

Francisco Cartujano, MD  ·  (585) 273-1646  ·  francisco_cartujano@urmc.rochester.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Rochester Medical CenterRochester, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06926608